Announcement • Jun 30
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥5.60, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 19x in the Healthcare industry in China. Total loss to shareholders of 16% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥8.63 per share. Reported Earnings • Apr 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.07 (in line with FY 2024). Revenue: CN¥10.4b (down 3.2% from FY 2024). Net income: CN¥285.3m (up 1.1% from FY 2024). Profit margin: 2.8% (up from 2.6% in FY 2024). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 33%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Apr 28
Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 19, 2026 Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 19, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China Announcement • Mar 31
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Buy Or Sell Opportunity • Mar 03
Now 27% undervalued Over the last 90 days, the stock has risen 25% to CN¥6.40. The fair value is estimated to be CN¥8.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 149% in the next 2 years. New Risk • Feb 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Feb 02
Now 21% undervalued Over the last 90 days, the stock has risen 22% to CN¥6.82. The fair value is estimated to be CN¥8.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.6% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 149% in the next 2 years. New Risk • Jan 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥6.13, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 1.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥8.61 per share. Announcement • Dec 31
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Fiscal Year 2025 Results on Apr 17, 2026 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report fiscal year 2025 results on Apr 17, 2026 Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥6.02, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 17x in the Healthcare industry in China. Total returns to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥8.61 per share. Price Target Changed • Nov 11
Price target increased by 8.6% to CN¥6.32 Up from CN¥5.82, the current price target is an average from 3 analysts. New target price is 15% above last closing price of CN¥5.49. Stock is up 8.9% over the past year. The company is forecast to post earnings per share of CN¥0.10 for next year compared to CN¥0.07 last year. Reported Earnings • Oct 31
Third quarter 2025 earnings released Third quarter 2025 results: EPS: CN¥0.033. Revenue: CN¥2.82b (down 4.1% from 3Q 2024). Net income: CN¥273.2m (up 14% from 3Q 2024). Profit margin: 9.7% (up from 8.2% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Reported Earnings • Sep 01
Second quarter 2025 earnings released: EPS: CN¥0.016 (vs CN¥0.023 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.016 (down from CN¥0.023 in 2Q 2024). Revenue: CN¥2.36b (down 2.0% from 2Q 2024). Net income: CN¥54.0m (down 24% from 2Q 2024). Profit margin: 2.3% (down from 2.9% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Aug 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 5.5% to CN¥5.13. The fair value is estimated to be CN¥6.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 81%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 184% in the next 2 years. Announcement • Jul 02
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 Declared Dividend • Jul 02
Dividend reduced to CN¥0.013 Dividend of CN¥0.013 is 29% lower than last year. Ex-date: 4th July 2025 Payment date: 4th July 2025 Dividend yield will be 0.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (18% earnings payout ratio) and cash flows (4% cash payout ratio). The dividend has increased by an average of 3.3% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 176% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Jun 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 8.9% to CN¥5.14. The fair value is estimated to be CN¥6.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 81%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 230% in the next 2 years. Buy Or Sell Opportunity • Jun 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to CN¥5.16. The fair value is estimated to be CN¥6.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 81%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 230% in the next 2 years. Buy Or Sell Opportunity • May 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 29% to CN¥5.18. The fair value is estimated to be CN¥6.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 81%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 235% in the next 2 years. Major Estimate Revision • May 09
Consensus EPS estimates fall by 26%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from CN¥11.3b to CN¥11.5b. EPS estimate fell from CN¥0.212 to CN¥0.157 per share. Net income forecast to grow 140% next year vs 19% growth forecast for Healthcare industry in China. Consensus price target up from CN¥5.82 to CN¥6.42. Share price was steady at CN¥5.34 over the past week. Buy Or Sell Opportunity • Apr 29
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to CN¥5.20. The fair value is estimated to be CN¥4.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.5% over the last 3 years. Earnings per share has grown by 76%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 41% per annum over the same time period. New Risk • Apr 17
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.6% Last year net profit margin: 4.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Reported Earnings • Apr 17
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.07 (down from CN¥0.13 in FY 2023). Revenue: CN¥10.7b (down 1.8% from FY 2023). Net income: CN¥282.2m (down 44% from FY 2023). Profit margin: 2.6% (down from 4.6% in FY 2023). Revenue missed analyst estimates by 6.7%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Mar 31
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥6.30, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.98 per share. New Risk • Feb 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Feb 17
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 46% to CN¥7.15. The fair value is estimated to be CN¥5.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 253% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥5.43, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥6.10 per share. Announcement • Dec 31
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Fiscal Year 2024 Results on Apr 17, 2025 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report fiscal year 2024 results on Apr 17, 2025 Buy Or Sell Opportunity • Dec 04
Now 23% undervalued Over the last 90 days, the stock has risen 40% to CN¥4.86. The fair value is estimated to be CN¥6.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 253% in the next 2 years. Buy Or Sell Opportunity • Nov 11
Now 20% undervalued Over the last 90 days, the stock has risen 36% to CN¥5.02. The fair value is estimated to be CN¥6.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 256% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥5.05, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥6.30 per share. Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.062 in 3Q 2023) Third quarter 2024 results: EPS: CN¥1.22 (up from CN¥0.062 in 3Q 2023). Revenue: CN¥2.94b (up 4.4% from 3Q 2023). Net income: CN¥240.4m (up 12% from 3Q 2023). Profit margin: 8.2% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Oct 17
Meinian Onehealth Healthcare Holdings Co., Ltd. Approves Appointment of Zhang Xiqiang as Independent Director Meinian Onehealth Healthcare Holdings Co., Ltd. at its 4th Extraordinary General Meeting of 2024 on 15 October 2024 approved appointment of Zhang Xiqiang as independent director. Announcement • Sep 30
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥3.94, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 15x in the Healthcare industry in China. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥4.31 per share. Buy Or Sell Opportunity • Sep 03
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥3.36. The fair value is estimated to be CN¥4.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 368% in the next 2 years. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.023 (vs CN¥0.047 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.023 (down from CN¥0.047 in 2Q 2023). Revenue: CN¥2.40b (up 3.0% from 2Q 2023). Net income: CN¥70.8m (down 60% from 2Q 2023). Profit margin: 2.9% (down from 7.6% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 23% per year. Buy Or Sell Opportunity • Jul 05
Now 20% overvalued Over the last 90 days, the stock has fallen 25% to CN¥3.74. The fair value is estimated to be CN¥3.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 34% in 2 years. Earnings are forecast to grow by 219% in the next 2 years. Announcement • Jun 29
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Jun 27
Meinian Onehealth Healthcare Holdings Co., Ltd. Announces Dividend Implementation for 2023, Payable on 04 July 2024 Meinian Onehealth Healthcare Holdings Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.19000000. Record date: 03 July 2024; Ex-date: 04 July 2024; Payment date: 04 July 2024. Price Target Changed • May 04
Price target decreased by 8.0% to CN¥7.54 Down from CN¥8.20, the current price target is an average from 3 analysts. New target price is 71% above last closing price of CN¥4.42. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥0.21 for next year compared to CN¥0.13 last year. Announcement • Apr 27
Meinian Onehealth Healthcare Holdings Co., Ltd. Proposes Final Cash Dividend for the Year 2023 Meinian Onehealth Healthcare Holdings Co., Ltd. proposed final cash dividend/10 shares (tax included) is CNY 0.19000000 for the year 2023. Announcement • Apr 26
Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 15, 2024 Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 15, 2024, at 14:30 China Standard Time. Location: 3F, Building 9, No. 697, Lingshi Road, Jing'an District, Shanghai China Reported Earnings • Apr 25
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥0.13 (up from CN¥0.14 loss in FY 2022). Revenue: CN¥10.9b (up 28% from FY 2022). Net income: CN¥505.6m (up CN¥1.04b from FY 2022). Profit margin: 4.6% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) missed analyst estimates by 3.7%. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. Announcement • Mar 30
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Buy Or Sell Opportunity • Feb 07
Now 21% overvalued Over the last 90 days, the stock has fallen 11% to CN¥5.32. The fair value is estimated to be CN¥4.40, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1,199% in the next 2 years. Announcement • Dec 30
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Price Target Changed • Nov 03
Price target increased by 7.5% to CN¥8.56 Up from CN¥7.96, the current price target is an average from 4 analysts. New target price is 41% above last closing price of CN¥6.07. Stock is up 23% over the past year. The company is forecast to post earnings per share of CN¥0.14 next year compared to a net loss per share of CN¥0.14 last year. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.062 (vs CN¥0.073 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.062 (down from CN¥0.073 in 3Q 2022). Revenue: CN¥2.81b (flat on 3Q 2022). Net income: CN¥215.5m (down 23% from 3Q 2022). Profit margin: 7.7% (down from 9.8% in 3Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.06 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.049 (up from CN¥0.06 loss in 2Q 2022). Revenue: CN¥2.31b (up 47% from 2Q 2022). Net income: CN¥177.3m (up CN¥412.7m from 2Q 2022). Profit margin: 7.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 26
Full year 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.02 profit in FY 2021) Full year 2022 results: CN¥0.14 loss per share (down from CN¥0.02 profit in FY 2021). Revenue: CN¥8.53b (down 6.8% from FY 2021). Net loss: CN¥533.1m (down CN¥597.3m from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to CN¥5.00 Down from CN¥5.60, the current price target is an average from 2 analysts. New target price is 15% below last closing price of CN¥5.88. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥0.063 for next year compared to CN¥0.02 last year. Board Change • Nov 16
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Director Chao Zhu was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.073 (vs CN¥0.044 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.073 (up from CN¥0.044 in 3Q 2021). Revenue: CN¥2.83b (up 15% from 3Q 2021). Net income: CN¥277.9m (up 49% from 3Q 2021). Profit margin: 9.8% (up from 7.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Second quarter 2022 earnings released: CN¥0.06 loss per share (vs CN¥0.001 loss in 2Q 2021) Second quarter 2022 results: CN¥0.06 loss per share (down from CN¥0.001 loss in 2Q 2021). Revenue: CN¥1.57b (down 23% from 2Q 2021). Net loss: CN¥235.4m (loss widened CN¥231.5m from 2Q 2021). Over the next year, revenue is forecast to grow 24%, compared to a 20% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Announcement • Aug 13
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report First Half, 2022 Results on Aug 31, 2022 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report first half, 2022 results on Aug 31, 2022 Reported Earnings • May 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: CN¥0.11 loss per share (vs CN¥0.11 loss in 1Q 2021). Revenue: CN¥1.35b (up 1.5% from 1Q 2021). Net loss: CN¥431.1m (loss widened 1.7% from 1Q 2021). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Non-Independent Director Xiaojun Wang was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 19
Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 17, 2022 Meinian Onehealth Healthcare Holdings Co., Ltd., Annual General Meeting, May 17, 2022, at 14:50 China Standard Time. Agenda: To consider the 2021 work report of the board of directors; to consider the 2021 work report of the supervisory committee; to consider the 2021 profit distribution plan; to consider the Reappointment of 2022 audit firm; to consider the 2022 estimated continuing connected transactions; to consider the 2022 remuneration for directors; to consider the 2022 remuneration for supervisors; and to consider the other matter also. Reported Earnings • Apr 17
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CN¥0.02 (down from CN¥0.14 in FY 2020). Revenue: CN¥9.16b (up 17% from FY 2020). Net income: CN¥64.1m (down 88% from FY 2020). Profit margin: 0.7% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 76%. Over the next year, revenue is forecast to grow 14%, compared to a 20% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥6.08, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.37 per share. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.044 (vs CN¥0.07 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.46b (down 5.4% from 3Q 2020). Net income: CN¥186.8m (down 30% from 3Q 2020). Profit margin: 7.6% (down from 10% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year. Price Target Changed • Sep 03
Price target decreased to CN¥8.50 Down from CN¥14.75, the current price target is an average from 2 analysts. New target price is 13% above last closing price of CN¥7.52. Stock is down 53% over the past year. Reported Earnings • Aug 31
Second quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.059 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CN¥2.04b (up 60% from 2Q 2020). Net loss: CN¥3.92m (loss narrowed 98% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥7.48, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 54% over the past three years. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥8.92, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 16x in the Healthcare industry in China. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥16.34 per share. Reported Earnings • May 02
First quarter 2021 earnings released: CN¥0.11 loss per share (vs CN¥0.15 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CN¥1.33b (up 149% from 1Q 2020). Net loss: CN¥423.8m (loss narrowed 29% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 13
Full year 2020 earnings released: EPS CN¥0.14 (vs CN¥0.23 loss in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥7.81b (down 8.3% from FY 2019). Net income: CN¥554.0m (up CN¥1.42b from FY 2019). Profit margin: 7.1% (up from net loss in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Announcement • Feb 24
Meinian Onehealth Healthcare Holdings Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021 Meinian Onehealth Healthcare Holdings Co., Ltd. announced that they will report fiscal year 2020 results on Apr 13, 2021 Is New 90 Day High Low • Feb 03
New 90-day high: CN¥15.95 The company is up 29% from its price of CN¥12.38 on 05 November 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥22.15 per share. Is New 90 Day High Low • Dec 18
New 90-day low: CN¥11.68 The company is down 26% from its price of CN¥15.79 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.87 per share. Price Target Changed • Nov 27
Price target lowered to CN¥16.63 Down from CN¥18.10, the current price target is an average from 4 analysts. The new target price is 37% above the current share price of CN¥12.14. As of last close, the stock is down 18% over the past year. Is New 90 Day High Low • Nov 04
New 90-day low: CN¥13.75 The company is down 14% from its price of CN¥15.90 on 06 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥20.73 per share. Analyst Estimate Surprise Post Earnings • Nov 01
Third-quarter earnings released: Revenue and earnings miss expectations Third-quarter revenue missed analyst estimates by 22% at CN¥2.60b. Earnings per share (EPS) also missed analyst estimates by 36% at CN¥0.07. Revenue is forecast to grow 76% over the next year, compared to a 31% growth forecast for the Healthcare industry in China. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥1.77b, with earnings decreasing by CN¥2.55b from the prior year. Total revenue was CN¥6.67b over the last 12 months, down 25% from the prior year. Is New 90 Day High Low • Sep 28
New 90-day low: CN¥13.90 The company is down 4.0% from its price of CN¥14.41 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥20.53 per share. 
